Your browser doesn't support javascript.
loading
Corrigendum to <' Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors' [Eur. J. Med. Chem. 211 (2021), 113109].
Alvarez, Rosa M; García, Ana Belén; Riesco-Fagundo, Concepción; Martín, José I; Varela, Carmen; Rodríguez Hergueta, Antonio; González Cantalapiedra, Esther; Oyarzabal, Julen; Di Geronimo, Bruno; Lorenzo, Milagros; Albarrán, M Isabel; Cebriá, Antonio; Cebrián, David; Martínez-González, Sonia; Blanco-Aparicio, Carmen; Pastor, Joaquín.
Afiliação
  • Alvarez RM; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • García AB; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Riesco-Fagundo C; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Martín JI; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Varela C; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Rodríguez Hergueta A; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • González Cantalapiedra E; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Oyarzabal J; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Di Geronimo B; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Lorenzo M; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Albarrán MI; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Cebriá A; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Cebrián D; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Martínez-González S; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Blanco-Aparicio C; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain.
  • Pastor J; Experimental Therapeutics Programme, Spanish National Cancer Research Centre (CNIO), C/ Melchor Fernández Almagro 3, E-28029, Madrid, Spain. Electronic address: jpastor@cnio.es.
Eur J Med Chem ; 224: 113703, 2021 Nov 15.
Article em En | MEDLINE | ID: mdl-34284231
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article